Navigation Links
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
Date:2/11/2009

t; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended October 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                             Media
    info@peregrineinc.com                                 Barbara Lindheim
    (800) 987-8256                                        (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... As reported by Lauren Hunter of ... 3 factors: smaller spaces, multi-generational access, and water consumption. ... 2014 lists, including this article on Freshome , ... a leading manufacturer of steam bath generators, has noticed ... smaller spaces and an effort to reduce water consumption. ...
(Date:7/26/2014)... 26, 2014 As reported in ... 23rd, new research by Palo Alto Networks shows that ... playbook, now focusing more on businesses and their digital ... become increasingly wise to their tactics over the years. ... Joe Caruso, talks about the evolution of 419 scams ...
(Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
(Date:7/26/2014)... July 26, 2014 Multiple sclerosis ... disseminata, is an inflammatory disease in which the ... and spinal cord are damaged. This damage disrupts ... to communicate, resulting in a wide range of ... psychiatric problems. Multiple sclerosis takes several forms, with ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
Breaking Medicine News(10 mins):Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
... A residential summer weight-loss camp markedly improved obese ... Pediatrics reports. A Saint Louis University ... index (BMI), physical fitness and blood pressure. "Weight ... the social environment to be successful," said Nadim Kanafani, ...
... diabetes may be related to trend toward less sleep, ... Adding to the many reasons why people should get adequate ... cause insulin resistance, a component of type 2 diabetes. , ... measured after a night of normal sleep (about eight hours) ...
... levels increased more than 50% after timing change, researchers say ... make better use of a vitamin D supplement if you ... Researchers at the Cleveland Clinic examined 17 patients with vitamin ... period of two to three months, the patients were told ...
... May 2010 -- An international team of researchers has ... with HER2 over-expressing breast cancer do not respond to ... research, presented at the IMPAKT Breast Cancer Conference in ... clinical trial design and treatment strategies in HER2 over-expressing ...
... to 10 million women take hormone therapies, which are ... hormones lost from inactive ovaries. Progestin is a hormone ... of estrogen therapy on the uterus. In studies sponsored ... found that estrogen and progestin in hormone therapies increase ...
... ... held liable of confirmation fraud if an employee responds falsely to a confirmation request. ... requests, new guidance from the standards-setting boards supporting the use of secure electronic confirmations now ... ...
Cached Medicine News:Health News:The biggest winners: Summer campers 2Health News:One Sleepless Night Ups Insulin Resistance 2Health News:Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:Brian Fox to Speak on Audit Confirmation Fraud at the 2010 IAPP Annual Forum and Expo 2
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... the new Vice President of Business Development. Peter has ... in a number of different business development positions with ... positions were primarily related to business development/sales management and ... 30 years makes him a key and strategic asset ...
(Date:7/25/2014)... MARLTON, N.J. , July 25, 2014 /PRNewswire/ ... visibility, brand protection and serialization solutions, has recently ... Business" that addresses current and future needs ... solutions for the old supply chain model no ... advances in technology, including the growth of mobile ...
(Date:7/25/2014)... 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... quarter of 2014 increased 11% versus the prior year ... for the second quarter of 2014 versus the prior ... in distributor inventory 2 . Earnings per diluted share ... 11% from the prior year period to $1.10."In the ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2Acsis Addresses Questions on the Modern Supply Chain 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34
... 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: ... fast-growing, profitable developer, manufacturer and seller of medicine and ... today that the Company will effect a two-for-one reverse ... minimum share price requirements in connection with its application ...
... 31, 2010 CVS Caremark (NYSE: CVS ... to acquire the Medicare Part D business of Universal ... billion.  Universal American is a leading Medicare Prescription Drug Plan ... acquisition will more than double the size of CVS ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
... Mono-M Test is a qualitative enzyme ... to Paul-Bunnell heterophil, Epstein-Barr virus capsid ... used in conjunction with Mono-G Test, ... serodiagnosis of infectious (EBV) mononucleosis and ...
... The ImmunoWELL VCA IgM Test is an ELISA ... to Epstein-Barr Virus viral capsid antigen (VCA) in ... used in conjunction with other testing such as ... EBV early antigen tests and/or heterophile tests, the ...
The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...
... ImmunoDOT is dot-blot assay system combining ... microwell, a purified antigen set at a ... membrane. Reactivity is detected using the same ... assays., ,ENA/DNA combines antigens detected in Auto ...
Medicine Products: